Joule Names Paul Snaith as New President and CEO

Joule Names Paul Snaith as New President and CEO

February 20, 2014

Bedford, MA – February 20, 2014 – Joule today announced the appointment of Paul Snaith as President and Chief Executive Officer, following his most recent post as Chief Operating Officer. He assumes the role from Noubar Afeyan, Executive Chairman and Founder of Joule, who had been serving as interim CEO.

Eleven Biotherapeutics Initiates Pivotal Phase 3 Clinical Study with EBI-005 in Dry Eye Disease

Eleven Biotherapeutics Initiates Pivotal Phase 3 Clinical Study with EBI-005 in Dry Eye Disease

February 18, 2014

Patient Randomization and Dosing Underway

Pronutria® Announces Launch of Two Clinical Trials

Pronutria® Announces Launch of Two Clinical Trials

February 13, 2014

Closes $12.25 Million in Series B Financing to Advance ProNutrein™ Product Candidates

Concert Pharmaceuticals Announces Pricing of Initial Public Offering

Concert Pharmaceuticals Announces Pricing of Initial Public Offering

February 13, 2014

LEXINGTON, Mass., Feb 13, 2014 (BUSINESS WIRE) -- Concert Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts. In addition, Concert has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the same price to cover over-allotments. The shares are scheduled to begin trading on the NASDAQ Global Market on February 13, 2014 under the ticker symbol "CNCE."

Tangent Medical Receives ISO 13485 Certification

Tangent Medical Receives ISO 13485 Certification

February 12, 2014

ANN ARBOR, MI – February 12, 2014 - Tangent Medical (www.tangentmedical.com), a manufacturer of IV therapy products and creator of the NovaCath™ Integrated IV Catheter System, announced it has been awarded ISO 13485:2003 from the British Standards Institution (BSI). ISO 13485:2003 certification is the internationally recognized quality standard for medical devices and diagnostics.

Eleven Biotherapeutics Prices Initial Public Offering

Eleven Biotherapeutics Prices Initial Public Offering

February 6, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Eleven.

Tetraphase Pharmaceuticals Names Craig Thompson Chief Operating Officer

Tetraphase Pharmaceuticals Names Craig Thompson Chief Operating Officer

February 4, 2014

Brings broad experience in successful antibiotic development and commercialization

T2 Biosystems Awarded Top Honor as ‘Most Promising Company’ at Personalized Medicine World Conference 2014

T2 Biosystems Awarded Top Honor as ‘Most Promising Company’ at Personalized Medicine World Conference 2014

January 30, 2014

— T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced that it has been awarded top honor as the “Most Promising Company” at the 2014 Personalized Medicine World Conference held in Mountain View, CA, January 27-28. T2 Biosystems was chosen from a group of 22 competitors in recognition of its strong business model and team, as well as its innovative T2MR technology.

Quanterix Awarded Grant from GE and the NFL’s Head Health Challenge

Quanterix Awarded Grant from GE and the NFL’s Head Health Challenge

January 23, 2014

Lexington, Mass. – January 23, 2014 – Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that they have been selected as a winner of the GE and NFL Head Health Challenge from more than 400 entries across 27 countries by a panel of leading healthcare experts in brain research, imaging technologies and advocates for the advancement of brain research.

Concert Pharmaceuticals Announces the Appointment of Ryan Daws as Chief Financial Officer

Concert Pharmaceuticals Announces the Appointment of Ryan Daws as Chief Financial Officer

January 23, 2014

LEXINGTON, MA – Concert Pharmaceuticals, Inc. today announced the appointment of Ryan Daws as Chief Financial Officer. Mr. Daws brings to Concert more than 15 years of capital markets and financial advisory experience in the biotechnology and healthcare industry.

“Ryan has a strong track record leading a variety of financings and strategic transactions in the healthcare industry,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “He adds depth to Concert’s management team as we progress our drug development pipeline and grow the company.”